FGF1 and cancer: As the low stability of wild-typeFGF1 limited its application as a targeting vector, we introducedthree point mutations (Q40P/S47I/H93G), which were reported to extendthe in vivo half-life of FGF1 from 0.26 to 150 h.26 To test the targeting effect of the conjugates, we chosea breast cancer cell line and a rhabdomyosarcoma cell line becausethese cancers often overexpress FGFRs.